WeissLaw LLP, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of BioClinica, Inc. (“BioClinica” or the “Company”) (NASDAQ: BIOC) arising from its agreement for BioClinica to be acquired by a holding company controlled by JLL Partners, Inc. (“JLL”) in a transaction valued at approximately $123 million. Under the terms of the proposed transaction BioClinica shareholders will receive $7.25 in cash for each BioClinica share they own.
WeissLaw LLP is investigating whether BioClinica’s Board acted in the best interests of its public shareholders by actively shopping the Company to maximize shareholder value for BioClinica’s public shareholders, prior to entering into the proposed transaction with JLL. Notably, one analyst set a price target for BioClinica at $9.00 per share. If you own BioClinica shares and would like more information about your rights as a shareholder or additional information concerning our investigation, please contact Michael A. Rogovin either by telephone at (888) 593-4771 or by email at
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded institutions and individuals and obtained important corporate governance in these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or issuing materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at
or fill out the form on our website,
Attorney Advertising. Past results do not guarantee a similar outcome.